{"title":"Turning foes into permissive hosts: manipulation of macrophage polarization by intracellular bacteria","authors":"Trung HM Pham , Denise M Monack","doi":"10.1016/j.coi.2023.102367","DOIUrl":"10.1016/j.coi.2023.102367","url":null,"abstract":"<div><p><span><span>Macrophages function as tissue-immune sentinels and mediate key antimicrobial responses against bacterial </span>pathogens<span>. Yet, they can also act as a cellular niche for intracellular bacteria, such as </span></span><span><em>Salmonella enterica</em></span>, to persist in infected tissues. Macrophages exhibit heterogeneous activation or polarization, states that are linked to differential antibacterial responses and bacteria permissiveness. Remarkably, recent studies demonstrate that <em>Salmonella</em><span><span> and other intracellular bacteria inject virulence effectors into the cellular cytoplasm to skew the macrophage polarization state and reprogram these </span>immune cells into a permissive niche. Here, we review mechanisms of macrophage reprogramming by </span><em>Salmonella</em><span><span> and highlight manipulation of macrophage polarization as a shared bacterial pathogenesis strategy. In addition, we discuss how the interplay of bacterial effector mechanisms, microenvironmental signals, and ontogeny may shape macrophage cell states and functions. Finally, we propose ideas of how further research will advance our understanding of macrophage functional diversity and </span>immunobiology.</span></p></div>","PeriodicalId":11361,"journal":{"name":"Current Opinion in Immunology","volume":"84 ","pages":"Article 102367"},"PeriodicalIF":7.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543482/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9776206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Moïse de Lavergne, Lucie Maisonneuve, Katrina Podsypanina, Bénédicte Manoury
{"title":"The role of the antigen processing machinery in the regulation and trafficking of intracellular -Toll-like receptor molecules","authors":"Moïse de Lavergne, Lucie Maisonneuve, Katrina Podsypanina, Bénédicte Manoury","doi":"10.1016/j.coi.2023.102375","DOIUrl":"10.1016/j.coi.2023.102375","url":null,"abstract":"<div><p><span>Intracellular Toll-like receptors (TLRs) are key components of the innate immune system. Their expression in antigen-presenting cells (APCs), and in particular dendritic cells (DCs), makes them critical in the induction of the </span>adaptive immune response<span><span><span>. In DCs, they interact with the chaperone UNC93B1 that mediates their trafficking from the </span>endoplasmic reticulum<span> (ER) to endosomes where they are cleaved by proteases<span> and activated. All these different steps are also shared by major histocompatibility complex class-II (MHCII) molecules. Here, we will discuss the tight relationship intracellular TLRs have with the </span></span></span>antigen processing machinery in APCs for their trafficking and activation.</span></p></div>","PeriodicalId":11361,"journal":{"name":"Current Opinion in Immunology","volume":"84 ","pages":"Article 102375"},"PeriodicalIF":7.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10028093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Pharma — manufacturing: the unappreciated and overlooked indispensable skill","authors":"Jenik Radon , Grace Pan","doi":"10.1016/j.coi.2023.102385","DOIUrl":"10.1016/j.coi.2023.102385","url":null,"abstract":"<div><p>The process of vaccine production, manufacturing, is time-intensive, complex, expensive, and highly technical, requiring close coordination and collaboration among multiple companies with different inputs, from active pharmaceutical ingredients to glass, and specializations, and with the supply chains spread across many countries. Covid-19 pandemic highlighted that neglecting and ignoring the need for a global effort in vaccine manufacturing and delivery can have alarming, and devastating, repercussions, especially when the world needs a robust healthcare ecosystem to make sure that all of us are safe. So, the natural question is: what does the world need to be well-prepared for the next virus; what does it take to have the manufacturing of vaccines become less concentrated in a few countries and centers and diversified to more countries so that distribution can be more universal, so that all of us are safe? First will need to be the political recognition, and the acceptance, that no country can do or supply everything alone in the pharmaceutical sector — no country can be an island —and that binding international agreements will need to be adopted to make access to medicine more equitable and secure around the world. Furthermore, and critically so, significant long-term sustained investment in human resources must be adopted to fill major gaps in expertise, starting with a robust educational system whose graduates have the knowledge, ability, and capacity to work in this technical industry. Only then, with a professional-educated labor force, can resilient pharma-manufacturing clusters be successfully built throughout the world, which can, and will, give life to the new health code: “No one is safe, until everyone is safe.”</p></div>","PeriodicalId":11361,"journal":{"name":"Current Opinion in Immunology","volume":"84 ","pages":"Article 102385"},"PeriodicalIF":7.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10234362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Major histocompatibility complex class I assembly within endolysosomal pathways","authors":"Eli Olson , Malini Raghavan","doi":"10.1016/j.coi.2023.102356","DOIUrl":"10.1016/j.coi.2023.102356","url":null,"abstract":"<div><p><span>Major histocompatibility complex<span> class I (MHC class I) molecules facilitate subcellular immune surveillance<span> by presenting peptides on the cell surface. MHC class I assembly with peptides generally happens in the endoplasmic reticulum (ER). Peptides are processed in the cytosol, transported into the ER, and assembled with MHC class I heavy and light chains. However, as many </span></span></span>pathogens reside within multiple subcellular organelles, peptide sampling across non-cytosolic compartments is also important. MHC class I molecules internalize from the cell surface into endosomes and constitutively traffic between endosomes and the cell surface. Within endosomes, MHC class I molecules assemble with both exogenous and endogenous antigens processed within these compartments. Human MHC classI polymorphisms, well known to affect ER assembly modes, also influence endosomal assembly outcomes, an area of current interest to the field.</p></div>","PeriodicalId":11361,"journal":{"name":"Current Opinion in Immunology","volume":"84 ","pages":"Article 102356"},"PeriodicalIF":7.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9694692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Harrison Sudholz , Rebecca B Delconte , Nicholas D Huntington
{"title":"Interleukin-15 cytokine checkpoints in natural killer cell anti-tumor immunity","authors":"Harrison Sudholz , Rebecca B Delconte , Nicholas D Huntington","doi":"10.1016/j.coi.2023.102364","DOIUrl":"10.1016/j.coi.2023.102364","url":null,"abstract":"<div><p><span><span><span>Over recent years, the use of immune checkpoint inhibitors<span> (ICI) has progressed to first and second-line treatments<span> in several cancer types, transforming patient outcomes. While these treatments target </span></span></span>T cell<span> checkpoints, such as PD-1, LAG3 and CTLA-4, their efficacy can be compromised through adaptive resistance whereby tumors acquire mutations in genes regulating </span></span>neoantigen presentation by MHC-I </span><span>[93]</span><span>. ICI-responsive tumor types such as advanced metastatic melanoma<span> typically have a high mutational burden and immune infiltration; however, most patients still do not benefit from ICI monotherapy for a number of reasons </span></span><span>[94]</span><span><span>. This highlights the need for novel immunotherapy strategies that evoke the immune control of tumor cells with low neoantigen/MHC-I expression, overcome immune suppressive </span>tumor microenvironments and promote tumor inflammation. In this regard, targeting natural killer (NK) cells may offer a solution to some of these bottlenecks.</span></p></div>","PeriodicalId":11361,"journal":{"name":"Current Opinion in Immunology","volume":"84 ","pages":"Article 102364"},"PeriodicalIF":7.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9778217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Developments in oral enterotoxigenic Escherichia coli vaccines","authors":"Ann-Mari Svennerholm, Anna Lundgren","doi":"10.1016/j.coi.2023.102372","DOIUrl":"10.1016/j.coi.2023.102372","url":null,"abstract":"<div><p>Enterotoxigenic <em>Escherichia coli</em> (ETEC) is a leading cause of diarrhea in children in developing countries and in travelers. WHO has affirmed ETEC as a priority vaccine target, but there is no licensed ETEC vaccine available yet. We here describe recent, promising developments of different live, inactivated, and subunit ETEC candidate vaccines expressing or containing nontoxic enterotoxin and/or colonization factor antigens with a focus on oral vaccines. Many of the ETEC candidate vaccines have been tested in clinical trials for safety and immunogenicity and some of them also for protective efficacy in field trials or in challenge studies.</p></div>","PeriodicalId":11361,"journal":{"name":"Current Opinion in Immunology","volume":"84 ","pages":"Article 102372"},"PeriodicalIF":7.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9908262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Commander-in-chief: monocytes rally the troops for defense against aspergillosis","authors":"Keyi Wang , Vanessa Espinosa , Amariliz Rivera","doi":"10.1016/j.coi.2023.102371","DOIUrl":"10.1016/j.coi.2023.102371","url":null,"abstract":"<div><p><span><span>The detrimental impact of fungal infections to </span>human health has steadily increased over the past decades. In October of 2022, the World Health Organization published the first ever fungal-pathogen priority list highlighting increased awareness of this problem, and the need for more research in this area. There were four distinct fungal pathogens identified as critical priority groups with </span><span><em>Aspergillus fumigatus</em><em> (Af)</em></span> being the only mold. <em>Af</em><span> is a common environmental fungus responsible for over 90% of invasive aspergillosis cases worldwide. Pulmonary protection against </span><em>Af</em><span><span> is critically dependent on innate effector cells with essential roles played by </span>neutrophils<span> and monocytes<span>. In this review, we will summarize our current understanding of how monocytes help orchestrate antifungal defense against </span></span></span><em>Af</em>.</p></div>","PeriodicalId":11361,"journal":{"name":"Current Opinion in Immunology","volume":"84 ","pages":"Article 102371"},"PeriodicalIF":7.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9908263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ameya R Kirtane , Chaoyang Tang , Dylan Freitas , Joshua D Bernstock , Giovanni Traverso
{"title":"Challenges and opportunities in the development of mucosal mRNA vaccines","authors":"Ameya R Kirtane , Chaoyang Tang , Dylan Freitas , Joshua D Bernstock , Giovanni Traverso","doi":"10.1016/j.coi.2023.102388","DOIUrl":"10.1016/j.coi.2023.102388","url":null,"abstract":"<div><p><span><span>mRNA vaccines have played a critical role in controlling the SARS-CoV-2 pandemic, and are being actively studied for use in other </span>diseases<span>. There is a growing interest in applying mRNA vaccines at mucosal surfaces as it enables access to a unique immune reservoir in a less-invasive manner. However, mucosal surfaces present several barriers to mRNA uptake, including degrading enzymes, </span></span>mucus<span>, and clearance mechanisms. In this mini-review, we discuss our understanding of the immune response to mucosal mRNA vaccines as it compares to systemic mRNA vaccines. We also highlight physical and chemical methods for enhancing mRNA uptake across mucosal tissues. Mucosal mRNA vaccination is a nascent field of research, which will greatly benefit from fundamental investigations into the mechanisms of immune activation and the development of technologies for improved delivery.</span></p></div>","PeriodicalId":11361,"journal":{"name":"Current Opinion in Immunology","volume":"85 ","pages":"Article 102388"},"PeriodicalIF":7.0,"publicationDate":"2023-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41180036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Tumor immune evasion through loss of MHC class-I antigen presentation","authors":"Gulce Sari, Kenneth L Rock","doi":"10.1016/j.coi.2023.102329","DOIUrl":"10.1016/j.coi.2023.102329","url":null,"abstract":"<div><p><span>CD8 T cells recognize cancers when they detect antigenic peptides presented on a tumor’s surface MHC-I molecules. Since MHC-I </span>antigen presentation<span> is not essential for cell growth or survival, many cancers inactivate this pathway, and thereby escape control by CD8 T cells. Such immune evasion allows cancers to progress and also become resistant to CD8 T- cell-based immunotherapies, such as checkpoint blockade. Here, we review recent findings about the various different mechanisms that cancers use to impair antigen presentation, the consequence of such changes, and, in some cases, the potential to reverse these defects.</span></p></div>","PeriodicalId":11361,"journal":{"name":"Current Opinion in Immunology","volume":"83 ","pages":"Article 102329"},"PeriodicalIF":7.0,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10524158/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9996985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"M1-aminopeptidase family — beyond antigen-trimming activities","authors":"Irini Evnouchidou , Despoina Koumantou , Mathilde Nugue , Loredana Saveanu","doi":"10.1016/j.coi.2023.102337","DOIUrl":"10.1016/j.coi.2023.102337","url":null,"abstract":"<div><p>Antigen (Ag)-trimming aminopeptidases belong to the oxytocinase subfamily of M1 metallopeptidases. In humans, this subfamily contains the endoplasmic reticulum aminopeptidases 1 and 2 (ERAP1 and 2) and the insulin-responsive aminopeptidase (IRAP, synonym oxytocinase), an endosomal enzyme. The ability of these enzymes to trim antigenic precursors and to generate major histocompatibility class-I ligands has been demonstrated extensively for ERAP1, less for ERAP2, which is absent in rodents, and exclusively in the context of cross-presentation for IRAP. During 20 years of research on these aminopeptidases, their enzymatic function has been very well characterized and their genetic association with autoimmune diseases, cancers, and infections is well established. The mechanisms by which these proteins are associated to human diseases are not always clear. This review discusses the Ag-trimming-independent functions of the oxytocinase subfamily of M1 aminopeptidases and the new questions raised by recent publications on IRAP and ERAP2.</p></div>","PeriodicalId":11361,"journal":{"name":"Current Opinion in Immunology","volume":"83 ","pages":"Article 102337"},"PeriodicalIF":7.0,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9997469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}